136 related articles for article (PubMed ID: 31063157)
21. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study.
Traby L; Kollars M; Eischer L; Eichinger S; Kyrle PA
PLoS One; 2012; 7(12):e51447. PubMed ID: 23240024
[TBL] [Abstract][Full Text] [Related]
22. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study.
Søgaard M; Nielsen PB; Skjøth F; Kjaeldgaard JN; Larsen TB
Cancer Med; 2019 Mar; 8(3):1044-1053. PubMed ID: 30767432
[TBL] [Abstract][Full Text] [Related]
23. Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study.
Takai S; Nakanishi N; Yokota I; Imai K; Yamada A; Kawasaki T; Kasahara T; Okada T; Sawada T; Matoba S
Sci Rep; 2022 Dec; 12(1):21569. PubMed ID: 36513734
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
[TBL] [Abstract][Full Text] [Related]
25. Plasma Fibrin Clot Properties Are Unfavorably Altered in Women following Venous Thromboembolism Associated with Combined Hormonal Contraception.
Piróg M; Piwowarczyk S; Undas A
Dis Markers; 2019; 2019():4923535. PubMed ID: 31827635
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
[TBL] [Abstract][Full Text] [Related]
27. Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
Zabczyk M; Natorska J; Bagoly Z; Sarkady F; Barath B; Katona E; Bryk A; Zettl K; Wisniewski JR; Undas A
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214340
[TBL] [Abstract][Full Text] [Related]
28. Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study.
Lim MS; Indran T; Cummins A; Bennett A; Wood E; Brown S; McQuilten Z; Tran H; Epi MC; Chan NC; Chunilal S
Semin Thromb Hemost; 2019 Mar; 45(2):187-195. PubMed ID: 30566971
[TBL] [Abstract][Full Text] [Related]
29. Prothrombotic Fibrin Clot Phenotype Is Associated With Recurrent Pulmonary Embolism After Discontinuation of Anticoagulant Therapy.
Zabczyk M; Plens K; Wojtowicz W; Undas A
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):365-373. PubMed ID: 28062504
[TBL] [Abstract][Full Text] [Related]
30. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
[TBL] [Abstract][Full Text] [Related]
31. Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis.
Goldman S; Frączek P; Szklanny K; Papuga-Szela E; Stanisz A; Undas A
Thromb Haemost; 2018 Apr; 118(4):654-663. PubMed ID: 29618152
[TBL] [Abstract][Full Text] [Related]
32. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
[TBL] [Abstract][Full Text] [Related]
34. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
Khorana AA; Weitz JI
Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
36. Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome.
Celinska-Löwenhoff M; Zabczyk M; Iwaniec T; Plens K; Musial J; Undas A
Rheumatology (Oxford); 2018 Aug; 57(8):1340-1349. PubMed ID: 29672756
[TBL] [Abstract][Full Text] [Related]
37. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
38. Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study.
Polak MW; Siudut J; Plens K; Undas A
J Thromb Thrombolysis; 2019 Nov; 48(4):603-609. PubMed ID: 31432450
[TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
[TBL] [Abstract][Full Text] [Related]
40. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
